Kyverna Therapeutics Aims for FDA Approval of First CAR-T Therapy for Stiff Person Syndrome

Kyverna Therapeutics is preparing to challenge the established boundaries of cell therapy, announcing plans to seek FDA approval for a personalized CAR-T treatment targeting stiff person syndrome—a rare and debilitating neurological autoimmune disorder. The company's one-time therapy demonstrated significant improvements in patient mobility and a reduction in disabilities, according to study results presented this week. This move positions Kyverna to potentially deliver the first-ever approved treatment for the condition and, more broadly, the first personalized CAR-T therapy for any autoimmune disease to reach the market.

The potential approval would mark a pivotal expansion for CAR-T technology, which is currently approved only for treating blood cancers. Kyverna's approach involves engineering a patient's own T cells to deplete B cells, effectively performing an 'immune system reset.' This strategy is at the forefront of a significant industry shift, with a growing number of biotech firms now redirecting their CAR-T research and development efforts toward autoimmune disorders, seeing them as the next frontier for the powerful cell therapy platform.

If successful, Kyverna's submission, expected by mid-year, would not only address a critical unmet medical need but also validate a new commercial and therapeutic pathway for the entire biotech sector. It signals intense competition and high-stakes investment in the race to adapt advanced cell therapies for chronic autoimmune conditions, potentially unlocking a vast new patient population and reshaping treatment paradigms beyond oncology.